Grit Biotechnology Receives U.S. FDA Clearance of Investigational New Drug Application for GT201, a genetically engineered TIL, following its Chinese IND Approval
SHANGHAI, Aug. 30, 2024 /PRNewswire/ -- Grit Biotechnology, a leading clinical-stage cell therapy company focusing on tumor-infiltrating lymphocyte (TIL) therapies, has...